

CLAIMS

Claim 1 (cancelled): A method of treating an individual suffering from acute liver failure, comprising administration of a therapeutically amount of mFLINT protein to said individual.

Claim 2 (cancelled): A method of treating an individual suffering from inflammation of the liver, comprising of a therapeutically amount of mFLINT protein to said individual.

Claim 3 (cancelled): A method of treating an individual suffering from abnormal hepatocyte apoptosis, comprising administration of a therapeutically amount of mFLINT protein to said individual.

Claim 4 (withdrawn): A method of treating an individual suffering from sepsis, comprising administration of a therapeutically amount of mFLINT protein to said individual.

Claim 5 (withdrawn): A method of treating an individual suffering from a disorder associated with inflammation, comprising administration of a therapeutically amount of mFLINT protein to said individual.

Claim 6 (cancelled): A method of treating an individual suffering from hepatitis, comprising administration of a therapeutically effective amount of mFLINT protein to said individual.

Claim 7 (withdrawn): A method of treating an individual suffering from abnormal apoptosis, comprising administration of a therapeutically effective amount of mFLINT protein to said individual.

Claim 8 (withdrawn): A method of treating an individual suffering from an ischemia-associated injury or disorder, comprising administration of a therapeutically effective amount of mFLINT protein to said individual.

Claim 9 (withdrawn): A method according to claim 8, wherein said injury or disorder is associated with hypercoagulation.

Serial No. 09/280,567
Docket X-12915

Claim 10 (withdrawn): A method according to claim 8, further comprising administration of an agent selected from the group selected from thrombolytic and antithrombotic agents.

Claim 11 (withdrawn): A method according to claim 10, wherein said antithrombotic agent is activated protein C.

Claim 12 (withdrawn): A method of treating an individual suffering from a reperfusion-associated injury or disorder, comprising administration of a therapeutically effective amount of mFLINT protein to said individual.

Claim 13 (withdrawn): A method of preventing damage to a cardiac myocyte in an individual that has suffered from abnormal myocardial ischemia, comprising administration of a therapeutically effective amount of mFLINT protein to said individual.

Claim 14 (withdrawn): A method of treating an individual suffering from Type I diabetes, comprising administration of a therapeutically amount of mFLINT protein to said individual.

Claim 15 (withdrawn): A method of treating an individual suffering from cancer, comprising administration of a therapeutically effective amount of mFLINT protein to said individual.

Claim 16 (withdrawn): A method of treating damage to an innocent bystander tissue that is induced by a chemotherapeutic agent or therapeutic irradiation, in an individual treated with said agent or irradiation, comprising administration of a therapeutically effective amount of mFLINT to said individual.

Claim 17 (withdrawn): A method according to claim 16, wherein said tissue is bone marrow.

Serial No. 09/280,567
Docket X-12915

Claim 18 (withdrawn): A method according to claim 16, wherein said tissue is the intestinal epithelium.

Claim 19 (withdrawn): A method according to claim 18, wherein said epithelium is in the oral cavity.

Claim 20 (withdrawn): A method of treating hematopoietic progenitor cells that have been exposed to therapeutic radiation of chemotherapy, comprising administering mFLINT to said cells.

Claim 21 (withdrawn): A method of promoting the growth or differentiation of a hematopoietic progenitor cell, comprising administering of mFLINT to said cell.

Claim 22 (withdrawn): A method of promoting the growth or differentiation of a CD34+ cell, comprising administering of mFLINT to said cell.

Claim 23 (withdrawn): A method for treating cancer, comprising treating bone marrow cells *in vitro* with mFLINT, and administering said cells to said patient, wherein said administration occurs after said patient has been treated with therapeutic irradiation or chemotherapy.

Claim 24 (withdrawn): A method according to claim 23, wherein said cells are from said patient.

Claim 25 (withdrawn): A method according to claim 23, wherein said cells are from an individual other than said patient.

Claim 26 (withdrawn): A method of treating cell damage in a patient who receives therapeutic irradiation or chemotherapy, comprising administering to said patient, a therapeutically effective amount of mFLINT with said irradiation or chemotherapy.

Serial No. 09/280,567
Docket X-12915

Claim 27 (withdrawn): A method according to claim 26, wherein said cell is an intestinal epithelial cell, a hematopoietic progenitor cell, or a peripheral blood cell.

Claim 28 (withdrawn): A method of treating aplastic anemia, comprising administering a therapeutically effective amount of mFLINT to a patient suffering from aplastic anemia.

Claim 29 (withdrawn): A method of treating a myelodysplastic syndrome, comprising administering a therapeutically effective amount of mFLINT to a patient suffering from said syndrome.

Claim 30 (withdrawn): A method of treating a pancytopenic condition, comprising administering a therapeutically effective amount of mFLINT to a patient suffering from said condition.

Claim 31 (withdrawn): An isolated nucleic acid molecule having the sequence of Figure 1.

Claim 32 (withdrawn): An isolated nucleic acid molecule having the sequence of Figure 3.

Claim 33 (withdrawn): An isolated polypeptide having the sequence of Figure 1.

Claim 34 (withdrawn): An isolated polypeptide having the sequence of Figure 3.

Claim 35 (withdrawn): A mouse comprising a transgene having the sequence of Figure 1.

Claim 36 (cancelled): A method of treating an individual suffering from acute liver failure, comprising administration of a therapeutically effective amount of FLINT protein to said individual.

Serial No. 09/280,567
Docket X-12915

Claim 37 (cancelled): A method of treating an individual suffering from inflammation of the liver, comprising administration of a therapeutically effective amount of FLINT protein to said individual.

Claim 38 (cancelled): A method of treating an individual suffering from abnormal hepatocyte apoptosis, comprising administration of a therapeutically effective amount of FLINT protein to said individual.

Claim 39 (cancelled): A method for treating an individual suffering from hepatitis, comprising administration of a therapeutically effective amount of FLINT protein to said individual.

Claim 40 (previously added): A method of treating an individual suffering from acute liver failure, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO: 6 or SEQ ID NO: 8 to said individual.

Claim 41 (previously added): A method of treating an individual suffering from inflammation of the liver, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO:6 or SEQ ID NO:8 to said individual.

Claim 42 (previously added): A method of treating an individual suffering from abnormal hepatocyte apoptosis, comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO:6 or SEQ ID NO:8 to said individual.

Claim 43 (previously added): A method of treating an individual suffering from hepatitis comprising administration of a therapeutically effective amount of a protein having the sequence as shown in SEQ ID NO:6 or SEQ ID NO:8 to said individual.